BioMarin’s ENERGY 3 trial of BMN 401 meets one co-primary endpoint
The trial showed that BMN 401 increased plasma PPi levels through week 52 versus the control group.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance